E
Xilio Therapeutics, Inc. XLO
$0.71 -$0.01-1.39% NASDAQ
Recommendation
Prev Close
$0.72
Volume
143,899
Avg Vol (90D)
2,708,680
Market Cap
$37.28M
Dividend & Yield
--
52-Week Range
$0.62 - $1.70
P/E (TTM)
--
EPS (TTM)
-$1.36
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Xilio Therapeutics GAAP EPS of -$0.18 misses by $0.28
5/8/2025 - Seeking Alpha - Healthcare
Xilio Therapeutics sees cash runway into 1Q26
5/8/2025 - The Fly
Xilio Therapeutics reports Q1 EPS (18c) vs. (62c) last year
5/8/2025 - The Fly
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results
5/8/2025 - Globe Newswire
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
5/2/2025 - Globe Newswire
Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, ...
4/23/2025 - GuruFocus
Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting
4/23/2025 - Globe Newswire
Gilead Sciences Inc. Purchases New Holdings in Xilio Therapeutics, Inc. (NASDAQ:XLO)
4/18/2025 - Ticker Report
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/4/2025 - GuruFocus
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/4/2025 - Globe Newswire
Xilio Therapeutics (NASDAQ:XLO) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS
3/13/2025 - Ticker Report
Xilio Therapeutics Reports 2024 Financial Results and Pipeline Progress
3/12/2025 - TipRanks Financial Blog
Xilio Therapeutics files $250M mixed securities shelf
3/11/2025 - The Fly
Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates
3/11/2025 - Zacks Investment Research
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year ...
3/11/2025 - GuruFocus
Xilio Therapeutics reports Q4 EPS (20c) vs (64c) last year
3/11/2025 - The Fly
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
3/11/2025 - Globe Newswire
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
2/24/2025 - GuruFocus
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
2/24/2025 - Globe Newswire
Analysts Offer Insights on Healthcare Companies: Ocugen (OCGN) and Xilio Therapeutics (XLO)
2/13/2025 - TipRanks Financial Blog
We're Hopeful That Xilio Therapeutics (NASDAQ:XLO) Will Use Its Cash Wisely
2/13/2025 - Simply Wall St
AbbVie and Xilio Therapeutics announce collaboration and option agreement
2/12/2025 - Seeking Alpha - Healthcare
AbbVie and Xilio Therapeutics Collaborate on Novel Tumor-Activated Immunotherapies
2/12/2025 - GuruFocus
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel ...
2/12/2025 - GuruFocus
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel ...
2/12/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$6.34M
EBITDA (TTM)
-$58.00M
EBIT (TTM)
-$59.65M
Net Income (TTM)
-$58.24M
Balance Sheet
Total Assets (Q)
$71.08M
Total Debt (Q)
$8.14M
Total Liabilities (Q)
$53.48M
Book Value Per Share (Q)
$0.3846
Cash Flow
Cash from Operations (TTM)
-$18.38M
Cash from Investing (TTM)
-$36.00K
Cash from Financing (TTM)
$29.20M
Net Change in Cash (TTM)
$10.78M
Filings
Filing Date
Tuesday, March 11, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
-0.46
7-Day Total Return
-7.27%
30-Day Total Return
-2.73%
60-Day Total Return
-52.03%
90-Day Total Return
-26.97%
Year to Date Total Return
-33.64%
1-Year Total Return
-43.65%
2-Year Total Return
-77.81%
3-Year Total Return
-78.42%
5-Year Total Return
--
52-week Low
Apr 07, 2025 - $0.62
52-week High
Feb 12, 2025 - $1.70
Valuation
Market Cap
$37.28M - Nano Cap
Enterprise Value
-$51.80M
Price/Sales (TTM)
7.35
Price/Book (Q)
1.87
Dividends and Shares
Shares Outstanding
64.68M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
xiliotx.com
Phone Number
857-524-2466
Address
828 Winter Street
Waltham, MA 02451
Country
United States
Year Founded
2016
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program... more
NASDAQ 05/09/2025 4:00PM Eastern Quotes delayed